Apheresis Market Size

Apheresis Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

In 2024 the apheresis market is expected to reach $ 2.5 billion and by 2035 is expected to reach $ 5.2 billion. The CAGR for this market is expected to be 6.86 percent. The increasing number of chronic diseases, the increasing demand for blood components and therapeutic apheresis procedures is the driving force behind this growth. Also, the development of apheresis devices that are more efficient and more patient-friendly is expected to drive market growth. Moreover, the leading players in the apheresis market such as Fresenius Kabi, Terumo BCT and Haemonetics are focusing on strategic developments to strengthen their market position. Strategic developments include the establishment of new technological alliances, the launch of new products and the development of new products to meet the changing needs of health care professionals. These factors are expected to have a significant impact on the future of the apheresis market.

Regional Market Size

Regional Deep Dive

The apheresis market is experiencing significant growth in all regions, driven by the increasing demand for blood components, advancements in technology and a rise in the prevalence of chronic diseases. North America is characterized by a well-developed health care system and high uptake of apheresis procedures. Europe features a diverse regulatory landscape and a market that is highly fragmented between countries. Asia-Pacific is characterized by rapid growth, driven by rising investments in health care and a growing patient population. Middle East and Africa (MEA) are gradually developing their apheresis capabilities, driven by improvements in the health care systems. Latin America is focusing on improving blood donation programs to meet local needs.

North America

• The recent approval of new apheresis devices, which increase the safety and efficiency of the procedure, will lead to an increase in the use of these devices by health care professionals.
• The blood transfusion industry is now in a position to compete in the global marketplace with the help of a number of innovations, such as the automation of apheresis systems, which have reduced the cost of blood transfusion and have improved patient outcomes.
• The high frequency of autoimmune diseases and hematological disorders in the region is expected to drive demand for therapeutic apheresis, which in turn will lead to increased treatment options and improved access to care.

Europe

• The European Medicines Agency (EM) has recently issued new guidelines on the use of apheresis for the treatment of various conditions, which are intended to improve the safety of this procedure in all member states.
• Germany and France are in the forefront of apheresis research, and organizations such as the German Red Cross Blood Donor Service have been at the forefront of research into the effectiveness of apheresis in treating certain diseases.
• European medicine is increasingly focused on individualised treatment. This has led to the development of new apheresis systems, which are able to meet the individual needs of the patient.

Asia-Pacific

• China and India are extending their apheresis capabilities rapidly, aided by government initiatives to improve blood donation and access to care.
• The introduction of inexpensive apheresis devices by local manufacturers has made the technology more accessible to hospitals and clinics in developing countries, and has thus increased the number of procedures.
• A collaboration between medical centres and technology companies is helping to develop new apheresis techniques, with the aim of improving the patient’s comfort and the efficiency of the procedure.

MEA

• In recent years, the World Health Organization has been working on the safety and availability of blood products in the Middle East and North Africa region.
• South Africa is investing in the modernization of its blood collection and processing facilities, including the integration of apheresis systems, in order to meet the growing demand for health care.
• The increase in the importance of blood donation is a factor that has influenced the positive growth of apheresis in the region.

Latin America

• Brazil has national programs to encourage voluntary blood donation, which will increase the availability of blood components for apheresis.
• The development of the apheresis equipment for the Latin American market is a crucial step in bringing these life-saving treatments to a wider audience.
• The apheresis market in this region is expected to grow as public health organizations and private sector players are coming together to enhance blood collection and processing capabilities.

Did You Know?

“The procedure of apheresis is not only used to collect blood components, but also to treat diseases such as multiple sclerosis and some forms of cancer.” — American Society for Apheresis

Segmental Market Size

The apheresis market is characterized by dynamic growth, driven primarily by the rising prevalence of chronic illnesses and the increasing demand for blood components. This market plays an important role in the treatment of hematological and autoimmune diseases. The emergence of personalized medicine and the growing focus on apheresis as a treatment method further increase the demand for apheresis and thus contribute to the growth of the apheresis market.

Advances in apheresis technology, which enhances the efficiency and safety of the procedure, as well as regulatory support, will drive the segment. The current market is in a stage of maturity, with the major players, such as Fresenius Kabi and Terumo BCT, driving the segment in North America and Europe. The major applications are therapeutic apheresis for conditions such as multiple sclerosis and autoimmune diseases. Also, the Influenza A (H1N1) pandemic and the sustainable blood policy will spur the market for convalescent plasma collection. Continuous flow centrifuges and automation of the apheresis procedure are shaping the future of the segment.

Future Outlook

The Apheresis Market is projected to grow at a CAGR of 6.86 percent between 2024 and 2035. This growth is due to the rising prevalence of chronic diseases, the increasing demand for blood components, and the advancement of apheresis technology. In the next 20 years, as the apheresis market continues to develop and as the world's health care systems continue to focus on patient-centric care, the penetration rate of apheresis is expected to increase to 15 to 20 percent in the targeted therapeutic areas by 2035, compared to the current estimated 10 percent.

The introduction of new technological innovations such as automatic apheresis and improved blood extraction systems are expected to further facilitate procedures and improve patient outcomes. In addition, supportive policies and regulatory frameworks to encourage blood donation and transfusion safety will support the growth of the market. Moreover, the integration of artificial intelligence in apheresis processes and the expansion of apheresis applications in regenerative medicine and in the field of immunotherapy are likely to further reshape the market. As these innovations take root, the market is expected to not only expand in terms of the number of procedures, but also in terms of the diversity of applications, thereby making apheresis an essential component of modern treatment strategies.